{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:36:26Z","timestamp":1787726186093,"version":"build-2784847793"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.intimp.2025.114337","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T08:14:17Z","timestamp":1740557657000},"page":"114337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Broad antifibrotic activities of AK3280 in pulmonary, hepatic, cardiac, and skin fibrosis animal models"],"prefix":"10.1016","volume":"151","author":[{"given":"Zhao","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim Zhen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.intimp.2025.114337_bb0005","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41584-019-0322-7","article-title":"Shared and distinct mechanisms of fibrosis","volume":"15","author":"Distler","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114337_bb0010","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41392-022-01070-3","article-title":"Targeting fibrosis, mechanisms and cilinical trials","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2025.114337_bb0015","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.intimp.2025.114337_bb0020","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1084\/jem.20110551","article-title":"Integrating mechanisms of pulmonary fibrosis","volume":"208","author":"Wynn","year":"2011","journal-title":"J. Exp. Med."},{"issue":"10120","key":"10.1016\/j.intimp.2025.114337_bb0025","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","article-title":"Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals","volume":"391","author":"Conrad","year":"2018","journal-title":"Lancet"},{"issue":"9888","key":"10.1016\/j.intimp.2025.114337_bb0030","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","article-title":"Chronic kidney disease: global dimension and perspectives","volume":"382","author":"Jha","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.intimp.2025.114337_bb0035","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3899\/jrheum.111106","article-title":"Epidemiology of systemic sclerosis in a large US managed care population","volume":"39","author":"Furst","year":"2012","journal-title":"J. Rheumatol."},{"issue":"12","key":"10.1016\/j.intimp.2025.114337_bb0040","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1056\/NEJMra1300575","article-title":"Fibrosis--a common pathway to organ injury and failure","volume":"372","author":"Rockey","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.intimp.2025.114337_bb0045","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nbt1114-1069","article-title":"Landmark approvals in idiopathic pulmonary fibrosis","volume":"32","author":"Ratner","year":"2014","journal-title":"Nat. Biotechnol."},{"issue":"8","key":"10.1016\/j.intimp.2025.114337_bb0050","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/s41587-022-01412-0","article-title":"Fighting fibrosis","volume":"40","author":"Senior","year":"2022","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.intimp.2025.114337_bb0055","doi-asserted-by":"crossref","first-page":"H512","DOI":"10.1152\/ajpheart.00137.2015","article-title":"Pirfenidone exhibits cardioprotective effects by regulating myocardial fibrosis and vascular permeability in pressure-overloaded hearts","volume":"309","author":"Yamagami","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114337_bb0060","doi-asserted-by":"crossref","first-page":"8729","DOI":"10.1038\/s41598-024-59395-8","article-title":"Combination of losartan with pirfenidone: a protective anti-fibrotic against pulmonary fibrosis induced by bleomycin in rats","volume":"14","author":"Amirkhosravi","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2025.114337_bb0065","doi-asserted-by":"crossref","DOI":"10.1038\/srep44754","article-title":"Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis","volume":"7","author":"Komiya","year":"2017","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.intimp.2025.114337_bb0070","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1165\/rcmb.2019-0328TR","article-title":"Pirfenidone: molecular mechanisms and potential clinical applications in lung disease","volume":"62","author":"Ruwanpura","year":"2020","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.intimp.2025.114337_bb0075","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.rmed.2017.07.062","article-title":"Therapeutic targets in idiopathic pulmonary fibrosis","volume":"131","author":"Kolb","year":"2017","journal-title":"Respir. Med."},{"issue":"22","key":"10.1016\/j.intimp.2025.114337_bb0080","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.intimp.2025.114337_bb0085","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"45","author":"Wollin","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.intimp.2025.114337_bb0090","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.rmed.2018.11.012","article-title":"Lung function outcomes in the INPULSIS((R)) trials of nintedanib in idiopathic pulmonary fibrosis","volume":"146","author":"Brown","year":"2019","journal-title":"Respir. Med."},{"issue":"22","key":"10.1016\/j.intimp.2025.114337_bb0095","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.114337_bb0100","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12931-018-0907-8","article-title":"Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis","volume":"19","author":"Yoon","year":"2018","journal-title":"Respir. Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.114337_bb0105","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48593-4","article-title":"Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis","volume":"9","author":"Kato","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2025.114337_bb0110","doi-asserted-by":"crossref","DOI":"10.1177\/1753466618800618","article-title":"Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience","volume":"12","author":"Rivera-Ortega","year":"2018","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.intimp.2025.114337_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2021.102051","article-title":"A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects","volume":"69","author":"Cheung","year":"2021","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2025.114337_bb0120","article-title":"A novel N-Arylpyridone compound alleviates the inflammatory and fibrotic reaction of silicosis by inhibiting the ASK1-p38 pathway and regulating macrophage polarization","volume":"13","author":"Fan","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.intimp.2025.114337_bb0125","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Nonalcoholic steatohepatitis clinical research, design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.intimp.2025.114337_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059348","article-title":"Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for \"active\" disease","volume":"8","author":"Peng","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.intimp.2025.114337_bb0135","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/cvr\/cvaa256","article-title":"The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction","volume":"117","author":"Withaar","year":"2021","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.114337_bb0140","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1038\/s41467-023-40639-6","article-title":"IRX2 regulates angiotensin II-induced cardiac fibrosis by transcriptionally activating EGR1 in male mice","volume":"14","author":"Ma","year":"2023","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.intimp.2025.114337_bb0145","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/CIRCRESAHA.115.306565","article-title":"Cardiac fibrosis: the fibroblast awakens","volume":"118","author":"Travers","year":"2016","journal-title":"Circ. Res."},{"issue":"8","key":"10.1016\/j.intimp.2025.114337_bb0150","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2021.12.009","article-title":"Clinical phenotypes of heart failure with preserved ejection fraction to select preclinical animal models","volume":"7","author":"van Ham","year":"2022","journal-title":"JACC Basic Transl. Sci."},{"issue":"7","key":"10.1016\/j.intimp.2025.114337_bb0155","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/echo.15628","article-title":"Myocardial performance index and cardiovascular diseases","volume":"40","author":"Askin","year":"2023","journal-title":"Echocardiography"},{"issue":"2","key":"10.1016\/j.intimp.2025.114337_bb0160","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10741-021-10105-w","article-title":"Biomarkers for the diagnosis and management of heart failure","volume":"27","author":"Castiglione","year":"2022","journal-title":"Heart Fail. Rev."},{"issue":"6","key":"10.1016\/j.intimp.2025.114337_bb0165","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1172\/JCI44824","article-title":"Pivotal role of cardiomyocyte TGF-beta signaling in the murine pathological response to sustained pressure overload","volume":"121","author":"Koitabashi","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.intimp.2025.114337_bb0170","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/wrr.12562","article-title":"Scar formation following excisional and burn injuries in a red Duroc pig model","volume":"25","author":"Blackstone","year":"2017","journal-title":"Wound Repair Regen."},{"issue":"1","key":"10.1016\/j.intimp.2025.114337_bb0175","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.burns.2008.06.020","article-title":"Potential cellular and molecular causes of hypertrophic scar formation","volume":"35","author":"van der Veer","year":"2009","journal-title":"Burns"},{"issue":"1","key":"10.1016\/j.intimp.2025.114337_bb0180","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/wrr.12381","article-title":"Exacerbated and prolonged inflammation impairs wound healing and increases scarring","volume":"24","author":"Qian","year":"2016","journal-title":"Wound Repair Regen."},{"issue":"12","key":"10.1016\/j.intimp.2025.114337_bb0185","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1073\/pnas.83.12.4167","article-title":"Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro","volume":"83","author":"Roberts","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.intimp.2025.114337_bb0190","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1046\/j.1524-475x.2000.00128.x","article-title":"Hypertrophic scar tissues and fibroblasts produce more transforming growth factor-beta1 mRNA and protein than normal skin and cells","volume":"8","author":"Wang","year":"2000","journal-title":"Wound Repair Regen."},{"issue":"1","key":"10.1016\/j.intimp.2025.114337_bb0195","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jcp.25879","article-title":"TGFbeta signaling and the control of myofibroblast differentiation: implications for chronic inflammatory disorders","volume":"233","author":"Carthy","year":"2018","journal-title":"J. Cell. Physiol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114337_bb0200","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1083\/jcb.122.1.103","article-title":"Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts","volume":"122","author":"Desmouliere","year":"1993","journal-title":"J. Cell Biol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114337_bb0205","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12931-018-0730-2","article-title":"Idiopathic pulmonary fibrosis: pathogenesis and management","volume":"19","author":"Sgalla","year":"2018","journal-title":"Respir. Res."},{"issue":"19","key":"10.1016\/j.intimp.2025.114337_bb0210","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra1705751","article-title":"Idiopathic pulmonary fibrosis","volume":"378","author":"Lederer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.114337_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107798","article-title":"Idiopathic pulmonary fibrosis: disease mechanisms and drug development","volume":"222","author":"Spagnolo","year":"2021","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2025.114337_bb0220","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12931-022-02027-4","article-title":"PEDF is an antifibrosis factor that inhibits the activation of fibroblasts in a bleomycin-induced pulmonary fibrosis rat model","volume":"23","author":"Qin","year":"2022","journal-title":"Respir. Res."},{"issue":"3","key":"10.1016\/j.intimp.2025.114337_bb0225","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s12015-017-9790-9","article-title":"Gene network analysis of interstitial macrophages after treatment with induced pluripotent stem cells Secretome (iPSC-cm) in the bleomycin injured rat lung","volume":"14","author":"Tamo","year":"2018","journal-title":"Stem Cell Rev. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2025.114337_bb0230","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"10290","key":"10.1016\/j.intimp.2025.114337_bb0235","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.intimp.2025.114337_bb0240","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.intimp.2025.114337_bb0245","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1055\/s-0035-1550065","article-title":"Fibrosis in nonalcoholic fatty liver disease: mechanisms and clinical implications","volume":"35","author":"Angulo","year":"2015","journal-title":"Semin. Liver Dis."},{"issue":"2","key":"10.1016\/j.intimp.2025.114337_bb0250","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.intimp.2025.114337_bb0255","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.intimp.2025.114337_bb0260","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.intimp.2025.114337_bb0265","doi-asserted-by":"crossref","DOI":"10.3390\/metabo11060374","article-title":"Metabolomic study of high-fat diet-induced obese (DIO) and DIO plus CCl(4)-induced NASH mice and the effect of Obeticholic acid","volume":"11","author":"Zhu","year":"2021","journal-title":"Metabolites"},{"issue":"10","key":"10.1016\/j.intimp.2025.114337_bb0270","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201910865","article-title":"Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?","volume":"12","author":"Sweeney","year":"2020","journal-title":"EMBO Mol. Med."},{"issue":"11 Pt 2","key":"10.1016\/j.intimp.2025.114337_bb0275","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/j.jcmg.2018.11.031","article-title":"Relationship between focal and diffuse fibrosis assessed by CMR and clinical outcomes in heart failure with preserved ejection fraction","volume":"12","author":"Kanagala","year":"2019","journal-title":"JACC Cardiovasc. Imaging"},{"issue":"5","key":"10.1016\/j.intimp.2025.114337_bb0280","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jacc.2020.05.072","article-title":"Effect of Sacubitril\/valsartan on biomarkers of extracellular matrix regulation in patients with HFpEF","volume":"76","author":"Cunningham","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.intimp.2025.114337_bb0285","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41569-020-0381-0","article-title":"Cardiac natriuretic peptides","volume":"17","author":"Goetze","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"issue":"8","key":"10.1016\/j.intimp.2025.114337_bb0290","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41591-021-01452-0","article-title":"Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial","volume":"27","author":"Lewis","year":"2021","journal-title":"Nat. Med."},{"issue":"7193","key":"10.1016\/j.intimp.2025.114337_bb0295","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nature07039","article-title":"Wound repair and regeneration","volume":"453","author":"Gurtner","year":"2008","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.intimp.2025.114337_bb0300","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/jid.2012.499","article-title":"The IL-6 trans-signaling-STAT3 pathway mediates ECM and cellular proliferation in fibroblasts from hypertrophic scar","volume":"133","author":"Ray","year":"2013","journal-title":"J. Invest. Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2025.114337_bb0305","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.burns.2011.12.012","article-title":"Post-burn hypertrophic scars are characterized by high levels of IL-1beta mRNA and protein and TNF-alpha type I receptors","volume":"38","author":"Salgado","year":"2012","journal-title":"Burns"},{"issue":"1","key":"10.1016\/j.intimp.2025.114337_bb0310","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/cphy.c170016","article-title":"Pathophysiologic mechanisms and current treatments for cutaneous sequelae of burn wounds","volume":"8","author":"Hall","year":"2017","journal-title":"Compr. Physiol."},{"issue":"Suppl. 1","key":"10.1016\/j.intimp.2025.114337_bb0315","first-page":"S32","article-title":"Review of the female Duroc\/Yorkshire pig model of human fibroproliferative scarring, Wound Repair Regen 15 Suppl","volume":"1","author":"Zhu","year":"2007"},{"issue":"6","key":"10.1016\/j.intimp.2025.114337_bb0320","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.burns.2006.03.015","article-title":"Histology of the thick scar on the female, red Duroc pig: final similarities to human hypertrophic scar","volume":"32","author":"Harunari","year":"2006","journal-title":"Burns"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925003273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925003273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T14:44:15Z","timestamp":1741272255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925003273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":64,"alternative-id":["S1567576925003273"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114337","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Broad antifibrotic activities of AK3280 in pulmonary, hepatic, cardiac, and skin fibrosis animal models","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114337","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114337"}}